New cocktail aims to tame Slow-Growing blood cancers

NCT ID NCT07609446

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase II trial will test a combination of pomalidomide, an anti-CD20 antibody, and prednisone as a first treatment for people with indolent (slow-growing) B-cell lymphomas. About 30 adults who have not had prior therapy will receive six cycles of the combo, followed by two years of maintenance. The main goal is to see how many patients respond, while also tracking side effects and how long the benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pomalidomide, anti-CD20 antibody (a targeted immune therapy), and prednisone (a steroid)
What this could lead to
If successful, this could offer a new first-line treatment option for indolent B-cell lymphoma that may improve response rates and delay disease progression.
What could go wrong
This is a small, early-phase (Phase II) trial with only 30 participants, so results may not apply broadly. The combination may cause side effects like low blood counts or infections, and it is not a cure—patients will need ongoing maintenance therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.